Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Gabapentin is FDA-approved as an add-on treatment for focal-onset seizures, helping improve seizure control alongside other therapies. Abstract Epilepsy is a chronic neurological disorder that manifests as a tendency to experience recurrent seizures. The management of epilepsy often involves the use of Antiepileptic Drugs (AEDs) to control seizure activity. Gabapentin, a commonly prescribed AED, has shown efficacy in the treatment of epilepsy. Gabapentin is 1 of many antiseizure medications available for the treatment of epilepsy in adults; however, there are potential risks associated with its use. Therefore, it is important to determine the place of therapy of gabapentin in the treatment of epilepsy. Doctors prescribe gabapentin to treat epilepsy, restless legs syndrome, and some types of nerve pain. Learn more the drug's uses, risks, and safety here. Gabapentin is a prescription drug used to treat seizure disorders and nerve damage from shingles. Off label uses (non-FDA approved) include fibromyalgia, headaches, and hot flashes. Common side effects are fatigue, nausea, hostility, dizziness, and tremors. Gabapentin is not an opioid narcotic, but it does have signs and symptoms associated with drug misuse, addiction, and withdrawal symptoms What Is the Issue? Gabapentin is 1 of many antiseizure medications available for the treatment of epilepsy in adults; however, there are potential risks associated with its use. Therefore, it is important to determine the place of therapy of gabapentin in the treatment of epilepsy. What Did We Do? To help determine the potential place in therapy for gabapentin in the treatment of epilepsy in Clinical Efficacy Understanding the clinical efficacy of gabapentin is crucial in evaluating its role as a treatment option for seizures. Clinical efficacy examines both the effectiveness of the drug in real-world settings and its capacity to improve patient outcomes. In epilepsy management, finding a suitable antiepileptic drug can vary based on seizure types, patient characteristics, and Abstract Background: Gabapentin is considered a safe and well-tolerated antipileptic drug (AED) with a favorable pharmacokinetic profile and a broad therapeutic index. However, recent studies have used higher doses and faster titration schedules than those used in the pivotal trials that established the efficacy of gabapentin in the treatment of partial seizures. Abstract Background: Epilepsy is one of the most common chronic neurological disorders, affecting more than 50 million people globally. In this review we summarised the evidence from randomised controlled trials of gabapentin used as monotherapy for the treatment of focal epilepsy, both newly diagnosed and drug-resistant, with or without secondary generalisation. The diversity of the current pipeline underscores a strong interest in the GABA system as a target for new treatment development in epilepsy. To date, limited clinical data are available for these investigational treatments and further studies are required to assess their potential value in addressing unmet needs in epilepsy management. Key Message What Is the Issue? Gabapentin is 1 of many antiseizure medications available for the treatment of epilepsy in adults; however, there are potential risks associated with its use. Therefore, it is important to determine the place of therapy of gabapentin in the treatment of epilepsy. What Did We Do? To help determine the potential place in therapy for gabapentin in the treatment of Gabapentin for Seizures: Drugs [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Oct. Table 9, Summary of Recommendations in Included Guidelines. Gabapentin is a Pfizer-made medication for focal aware and impaired seizures. For more information, visit the Epilepsy Foundation online The new antiepileptic medications are prescribed for the treatment of patients with seizure disorders since 17 years ago. Gabapentin (GBP) was approved on January 1994 as adjunctive treatment in patients 12 years or older with partial seizures, with Explore gabapentin's role as an adjunctive treatment for seizures, its benefits, effectiveness, and side effects in managing epilepsy and focal seizures. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of gabapentin monotherapy for people with epileptic partial seizures with and without secondary generalisation. Topiramate and zonisamide are anticonvulsants approved for the treatment of seizure disorders and migraines and for the adjunctive treatment of partial seizures, respectively. Zonisamide has a unique and multifaceted pharmacological profile; like topiramate, it blocks voltage-dependent sodium channels and inhibits carbonic anhydrase [49, 50]. Further trials are needed to assess the long‐term effects of gabapentin, and to compare gabapentin with other add‐on drugs. Plain language summary Gabapentin as an add‐on for drug‐resistant focal epilepsy Background Epilepsy is a disorder where recurrent seizures (fits) are caused by abnormal electrical discharges from the brain. The management of epilepsy typically involves the use of Antiepileptic Drugs (AEDs) to control seizure activity and improve the quality of life for individuals living with the condition. Among the wide range of AEDs available, gabapentin has emerged as a valuable treatment option for epilepsy [1]. What Is the Issue? Gabapentin is 1 of many antiseizure medications available for the treatment of epilepsy in adults; however, there are potential risks associated with its use. Therefore, it is important to determine the place of therapy of gabapentin in the treatment of epilepsy. What Did We Do? To help determine the potential place in therapy for gabapentin in the treatment of epilepsy in
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |